8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 19, 2026·SEC
Assembly Biosciences, Inc.(ASMB)Earnings, Financials & Key Ratios
ASMB•NASDAQ
$28.96
Price updated Jul 7, 2026
AboutAssembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Show more
- Revenue$72M+153.5%
- EBITDA-$12M+73.5%
- Net Income-$6M+84.8%
- EPS (Diluted)-0.55+91.8%
- Gross Margin99.82%-0.2%
- EBITDA Margin-16.58%+89.6%
- Operating Margin-16.76%+89.5%
- Net Margin-8.47%+94.0%
- ROE-5.1%+95.3%
ASMB Price & Volume
Assembly Biosciences, Inc. (ASMB) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependence Masks Underlying Clinical Burn Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial failure risk
Key Thesis Takeaways
- Assembly Biosciences remains a high-risk clinical-stage entity whose financial profile is dictated by episodic milestone payments rather than sustainable commercial operations.
- While the company maintains a lean capital expenditure profile, the persistent accumulation of an $841.1 million deficit underscores the significant capital intensity required to advance its HBV pipeline.
- Investors should remain cautious, as the firm's reliance on non-recurring revenue creates extreme volatility in cash flow and obscures the true operational burn rate.
Verdict Logic
the company's reliance on non-recurring revenue to offset an operating margin of -138.4% in 2026Q1 suggests a precarious financial foundation that lacks a reliable commercial floor.
ASMB Growth Metrics
Assembly Biosciences, Inc. (ASMB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-1.78%
3 Years-
TTM121.11%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM84.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM90.91%
Return on Capital
10 Years-45.35%
5 Years-53.29%
3 Years-44.34%
Last Year-8.65%
ASMB Recent Earnings
Assembly Biosciences, Inc. (ASMB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.54+26.0%
$0.73
Rev
$8M-11.4%
$9M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$2.48+586.3%
$0.51
Rev
$42M+472.2%
$7M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.72-44.0%
$0.50
Rev
$11M+44.6%
$7M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.33-103.6%
$0.65
Rev
$10M+3.2%
$9M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.54vs $0.73+26.0% | $8Mvs $9M-11.4% |
| Q2 2026 | Mar 19, 2026 | $2.48vs $0.51+586.3% | $42Mvs $7M+472.2% |
| Q4 2025 | Nov 10, 2025 | $0.72vs $0.50-44.0% | $11Mvs $7M+44.6% |
| Q3 2025 | Aug 6, 2025 | $1.33vs $0.65-103.6% | $10Mvs $9M+3.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Assembly Biosciences, Inc. (ASMB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.97 | $460.33M | -52.66 | 153.52% | -8.47% | -5.1% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $11.51 | $966.21M | -3.41 | — | — | -128.57% | — | |
| $136.36 | $169.3B | 20.11 | 2.39% | 30.99% | 42.33% | — | |
| $676.23 | $70.26B | 16.30 | 0.99% | 29.65% | 14.32% | — |
Compare ASMB vs Peers
Assembly Biosciences, Inc. (ASMB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASMB SEC Filings & Documents
Assembly Biosciences, Inc. (ASMB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ASMB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ASMB Frequently Asked Questions
Assembly Biosciences, Inc. (ASMB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Assembly Biosciences, Inc.'s revenue?
Assembly Biosciences, Inc. (ASMB) reported $71.1M in revenue for fiscal year 2025.
How fast is Assembly Biosciences, Inc. growing?
Assembly Biosciences, Inc. (ASMB) grew revenue by 153.5% over the past year. This is strong growth.
Is ASMB profitable?
Assembly Biosciences, Inc. (ASMB) reported a net loss of $6.4M for fiscal year 2025.
Dividend & Returns
What is ASMB's return on equity?
Assembly Biosciences, Inc. (ASMB) has a return on equity (ROE) of -5.1%. Negative ROE indicates the company is unprofitable.
What is Assembly Biosciences, Inc.'s free cash flow?
Assembly Biosciences, Inc. (ASMB) had negative free cash flow of $39.8M in fiscal year 2025, likely due to heavy capital investments.